Haywood Securities set a $3.00 price target on Cannara Biotech (CNSX:LOVE – Free Report) in a report published on Monday,BayStreet.CA reports. The firm currently has a buy rating on the stock.
Separately, TD Securities set a $3.25 price target on shares of Cannara Biotech and gave the company a “buy” rating in a research report on Tuesday, February 24th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Cannara Biotech presently has a consensus rating of “Buy” and an average target price of $3.13.
Check Out Our Latest Stock Report on LOVE
Cannara Biotech Stock Performance
About Cannara Biotech
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
Featured Articles
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
